HUNT RONALD 4

What Happened

• Ronald Hunt, a director of Rallybio Corp (RLYB), was granted a derivative award on 2026-02-18 covering 14,305 shares with a strike/receipt price of $3.60 per share (total value about $51,498). The Form 4 was filed on 2026-02-20.
• This was an award/option grant (not a sale or open-market purchase). The grant was issued in lieu of director retainer fees (see footnote).

Key Details

• Transaction date: 2026-02-18; Filing date: 2026-02-20 (timely).
• Instrument: derivative award/option for 14,305 shares at $3.60 per share; reported total ~$51,498 (footnote cites ~$51,500 in lieu of retainer fees).
• Vesting: vests in 11 equal installments, each on the last day of each remaining month of calendar year 2026 (footnote F1).
• Plan: issued under the Company’s 2021 Equity Incentive Plan (footnote F2).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing status: timely (no late filing indicated).

Context

• This was a compensation-related option grant to a director (issued instead of retainer fees), not an immediate cash purchase or sale. The award vests over monthly installments through the end of 2026, so the underlying shares will only become exercisable/owned as they vest.